IOM (Institute of Medicine). 2007. Global Infectious Disease Surveillance and Detection: Assessing the Challenges—Finding Solutions: Workshop Summary. Washington, DC: The National Academies Press.
IOM. 2009a. Breakthrough Business Models: Drug Development for Rare and NeglectedDiseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press.
IOM. 2009b. The U.S. Commitment to Global Health: Recommendations for the Public andPrivate Sectors. Washington, DC: The National Academies Press.
IOM. 2009c (June 1). Transcript, Fifth National Stakeholder Meeting of the IOM Committeeon Review of Priorities in the National Vaccine Plan. Seattle, Washington: IOM.
Kamara, L., J.B. Milstien, M. Patyna, P. Lydon, A. Levin, and L. Brenzel. 2008. Strategies for financial sustainability of immunization programs: A review of the strategies from 50 national immunization program financial sustainability plans. Vaccine 26(51):6717-6726.
Kieny, M.P., and M.P. Girard. 2005. Human vaccine research and development: An overview. Vaccine 23(50):5705-5707.
Letourneau, M., G. Wells, W. Walop, and P. Duclos. 2008. Improving global monitoring of vaccine safety: A quantitative analysis of adverse event reports in the WHO adverse reactions database. Vaccine 26(9):1185-1194.
Levine, O.S., T. Cherian, R. Hajjeh, and M. Deloria Knoll. 2009. Progress and future challenges in coordinated surveillance and detection of pneumococcal and Hib disease in developing countries. Clin Infect Dis 48(s2):S33-S36.
Lieu, T.A., T.G. McGuire, and A.R. Hinman. 2005. Overcoming economic barriers to the optimal use of vaccines. Health Aff 24(3):666-679.
Lydon, P., A. Jones, and L. Kamara. 2007 (April 17). Changing Context of ImmunizationFinancing—Issues For Future Immunization Efforts. Presentation at the Strategic Advisory Group of Experts on Immunization Financing Meeting. Varembé, Geneva: World Health Organization.
Mahmoud, A. 2005. The vaccine enterprise: Time to act. Health Aff 24(3):596-597.
Milstien, J.B., M. Kaddar, and M.P. Kieny. 2006. The impact of globalization on vaccine development and availability. Health Aff 25(4):1061-1069.
NVAC (National Vaccine Advisory Committee). 1997. United States vaccine research: A delicate fabric of public and private collaboration. Pediatrics 100(6):1015-1020.
Oxfam. 2008. Ending the R&D crisis in public health: Promoting pro-poor medical innovation. Oxfam Briefing Paper:122.
Reingold, A.L., C.V. Broome, A.W. Hightower, G.W. Ajello, G.A. Bolan, and C. Adamsbaum. 1985. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2:114-118.